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Background: Pediatric neurofibromatosis type 1 (NF1) patients rarely develop
aggressive central nervous system tumors. Among high-grade gliomas (HGGs), histone
mutant diffuse midline gliomas (DMGs H3 K27M-mutant) have exceptionally been
reported. The aim of this retrospectives single-center study was to compare the clinical
behavior of DMGs H3 K27M-mutant and non-histone mutant midline HGGs in NF1 vs.
non-syndromic children and to report imaging features of NF1 HGGs.
Method: We conducted a retrospective review of cerebral DMGs H3 K27M-mutant or
non-histone mutant HGGs in 18 patients with or without NF1 followed at our institution
between 2010 and 2018. Differences in outcomes, notably progression-free survival
(PFS) and overall survival (OS), were evaluated.
Results: Two patients were identified with genetically confirmed diagnosis of NF1 and
cerebral HGGs (one DMG H3 K27M-mutant and one histone wild type). Both subjects
presented with midline mass lesions with imaging features of aggressive biological
activity on advanced MRI or amino-acid PET. During the same time period, 16 non-NF1
patients (11 subjects with DMGs H3 K27M-mutant and 5 with non-histone mutant
midline HGGs) were treated at our institution. The two patients with NF1 and HGGs
presented a PFS of 3 months and an OS of 5 and 7 months. Median PFS and OS of
children without NF1 were respectively 6 and 10 months in DMGs H3 K27M-mutant,
and 6 and 11 months in H3 K27M wild-type tumors. Seventy-five percent of subjects
with non-NF1 HGGs presented a PFS >4 months compared to 0% in NF1 patients. The
8-month OS of patients with non-NF1 HGGs was 81% compared to 0% in NF1 patients.
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Conclusions: Cerebral HGGs arising in midline structures rarely occur in pediatric
patients with NF1 and present with extremely poor prognosis, worse than
HGGs developing in non-NF1 patients, independent of the presence or absence
of H3 K27M mutation. Imaging features of aggressive biological activity on
advanced MRI or amino-acid PET imaging suggest prompt neuropathological and
molecular investigations.
Keywords: H3K27M, pediatric, brain tumor, diffuse midline glioma, NF1
INTRODUCTION
Neurofibromatosis type 1 (NF1) is the most frequent hereditary
cancer predisposition syndrome and is caused by germline
mutations in the NF1 gene encoding for neurofibromin, a very
large cytoplasmic protein that functions as a negative regulator of
RAS oncoproteins (1, 2). Aberrant regulation of RAS is believed
to contribute to increased cell proliferation and tumorigenesis.
Indeed, patients withNF1 have an increased likelihood to develop
benign and malignant tumors of the central and peripheral
nervous system (3–5). The most common central nervous system
(CNS) tumor in NF1 is optic pathway glioma, which occurs in
∼15–20% of pediatric patients (4, 6). These tumors are often
asymptomatic, very slowly progressive, and only rarely require
specific treatment (4, 5), with possible spontaneous regression
(7). Rarely, pediatric patients with NF1 may develop more
aggressive CNS tumors, including high-grade gliomas (HGGs)
(8). Of note, the overall survival (OS) of NF1 patients with
HGGs has been reported to be higher than their sporadic
counterparts (9).
The revised 2016 World Health Organization (WHO)
classification of tumors of the CNS introduced the diffusemidline
glioma (DMG) H3 K27M-mutant as a completely new entity.
DMG H3 K27M-mutant arises in all midline CNS structures
with the most common locations being the brainstem, thalamus,
and spinal cord. Among infiltrative brainstem gliomas, the vast
majority is represented by diffuse intrinsic pontine gliomas
(DIPGs), in which H3 K27M mutation occurs in about 85% of
cases (10). The detection of H3 K27M mutation in infiltrating
midline gliomas determines an assignment to WHO grade
IV (11).
The aim of this retrospective single-center study was
to compare the clinical behavior of DMGs H3 K27M-
mutant and non-histone mutant midline HGGs in NF1
vs. non-syndromic children and to report imaging features
of NF1 HGGs.
MATERIALS AND METHODS
After approval from the Institutional Review Board (Regional
Ethics committee of Liguria, Genoa, Italy), we performed a
retrospective review of the electronic database of our Neuro-
oncology Unit to identify potential patients admitted between
2010 and 2018. This time interval was selected because
all patients diagnosed since 2010 with diffusely infiltrating
astrocytic tumors arising in midline brain structures, with
available pathologic tissue, underwent retrospective molecular
analysis and categorization according to the revised 2016
WHO classification. In our search, we used the key terms
“NF1,” “neurofibromatosis type 1,” “anaplastic astrocytoma,”
“glioblastoma,” and “DMG.” Patients were included for analysis
only if they (i) met neuroimaging criteria for cerebral midline
location (thalamic, brainstem, or diencephalic–mesencephalic
junction); (ii) underwent molecular analysis for H3 K27M; (iii)
met the clinical criteria for NF1, established by the National
Institutes of Health; and (iv) had genetically confirmed NF1
diagnosis. An additional search was performed to identify
non-NF1 patients with cerebral DMGs as defined by WHO
classification, non-histone mutant midline glioblastomas,
or midline anaplastic astrocytomas who received definitive
treatment at our institution during the same time period.
Patient age, diagnosis, clinical course, treatment plan, and
follow-up were reviewed. In particular, progression-free survival
(PFS) and OS (defined as the interval between initial diagnosis
and the onset of disease progression and of death from any cause,
respectively) were obtained.
Differences in PFS and OS between non-NF1 patients with
and without H3 K27M mutation were evaluated by the Kaplan–
Meier method and compared across groups by the log-rank
test. Statistical analysis was performed by using SPSS Statistics
for Mac, version 21.0 (IBM, Armonk, NY). A p- value of 0.05 was
used to define nominal statistical significance.
RESULTS
Two pediatric patients were identified who met criteria for
NF1 and had a DMG H3 K27M-mutant (ponto-mesencephalic
gliobastoma) and a thalamic anaplastic astrocytoma, H3 K27M-
wild type. During the same time period, 16 non-NF1 patients
with HGGs (11 DMGs H3 K27M-mutant and 5 non-histone
mutant HGGs) were treated at our institution. All subjects
with DMGs H3 K27M-mutant presented mutations in the
histone variant H3.3 (H3F3A). Ten non-NF1 children had been
previously included in a retrospective study aimed to evaluate
the diagnostic ability of 18F-dihydroxyphenylalanine (DOPA)
PET and advanced MRI techniques in discriminating DMGs H3
K27M-mutant from non-histone mutant midline gliomas (12).
Location and neuropathological and clinical features (treatments
and outcome) of NF1 and non-NF1 patients are reported in
Table 1.
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1 12 M GB H3K27M-m L-Th IV PS/RT/VIN+NIM/TEM PD 6 14
2 3 F GB H3K27M-m R-Th/L-Th IV B/RT/VIN+NIM PD and DOD 9 13
3 10 M GB H3K27M-m Pons IV B/RT/VIN+NIM/TEM+ETO PD and DOD 4 6
4 12 F GB H3K27M-m Medulla IV B/ RT/VIN+NIM/DAB+TRA PD and DOD 5 9
5 6 F GB H3K27M-m R-DMJ IV B/RT/TEM+BEV PD and DOD 4 8
6 6 M GB H3K27M-m Pons IV B/RT/VIN+NIM PD 6 10
7 7 M AA H3K27M-m Pons IV B/RT/VIN+NIM/IRI/SIR PD and DOD 7 10
8 8 F AA H3K27M-m Pons IV B/RT/VIN+NIM PD and DOD 6 12
9 16 F AA H3K27M-m R-DMJ IV B/RT/TEM+BEV PD and DOD 5 6
10 10 F AA H3K27M-m R-Th IV B/RT/TEM+BEV PD and DOD 10 18
11 3 F AA H3K27M-m R-Th IV B/RT/TEM PD and DOD 4 8
12 6 M GB H3K27M-wt L-Th IV B/RT/TEM+BEV PD and DOD 6 10
13 9 M GB H3K27M-wt L-Th IV PS/RT/CAR+VC/TEM/BEV+ETO PD and DOD 4 7
14 9 M GB H3K27M-wt R-Th IV B/RT/TEM+BEV/POM/ETO PD and DOD 5 11
15 11 M AA H3K27M-wt R-Th/L-Th III B/RT/TEM PD and DOD 6 12
16 17 F AA H3K27M-wt R-Th/L-Th III PS/RT/TEM+BEV/VIN+RAP PD and DOD 8 12
NF1 HIGH-GRADE GLIOMAS
1 11 F GB H3K27M-m L-Pons
midbrain
IV B/RT/VIN+NIM/ETO+TEM PD and DOD 3 7
2 13 F AA H3K27M-wt R-Th/L-Th III B/RT/TEM+VIN PD and DOD 3 5
PFS, progression-free survival; OS, overall survival; M, male; F, female; GB, glioblastoma; AA, anaplastic astrocytoma; m, mutant; wt, wild type; R, right; L, left; Th, thalamus; DMJ,
diencephalic-mesencephalic junction; B, biopsy; PS, partial surgery; RT, radiotherapy; VIN, vinorelbine; NIM, nimotuzumab; TEM, temozolomide; ETO, etoposide; DAB, dabrafenib; TRA,
trametinib; BEV, bevacizumab; IRI, irinotecan; SIR, sirolimus; CAR, carboplatin; VC, vincristine; POM, pomalidomide; RAP, rapamycin; PD, progressive disease; DOD, death of disease.
The two pediatric patients with NF1 presented a PFS of 3
months and an OS of 5 and 7 months. Median PFS and OS in
non-NF1 children were, respectively 6 and 10 months (PFS range
4–10 months, OS range 6–18 months). In detail, median PFS and
OS were 6 and 10 months in non-NF1 DMGs H3 K27M-mutant
(PFS range, 4–10 months; OS range, 6–18 months), and 6 and 11
months in non-histone mutant midline HGGs (PFS range, 4–9
months; OS range, 7–14 months).
Leptomeningeal dissemination was diagnosed during follow-
up in one NF1 DMG H3 K27M-mutant. Among non-NF1
HGGs, it was revealed in 3 out of 11 patients with DMGs H3
K27M-mutant and in 1 out of 5 non-histone mutant midline
HGGs. In all subjects, leptomeningeal dissemination was better
recognizable and much more prominent in the spinal region;
none of the patients presented leptomeningeal dissemination
at admission.
No statistically significant differences in terms of PFS and
OS emerged between non-NF1 subjects with DMGs H3 K27M-
mutant and non-histone mutant midline HGGs [χ2(2) = 0.114,
p < 0.736 and χ2(2) = 0.000003, p < 0.989, respectively].
While the small number of patients with NF1 precludes
formal statistical analysis, 75% of subjects with non-NF1 HGGs
presented a PFS>4months compared to 0% inNF1 patients. The
8-month OS of patients with non-NF1 HGGs was 81% compared
to 0% in NF1 patients. A description of each of the two NF1
cases follows.
Case 1
This 11-year-old female presented a few days’ history of
headache, vomiting, difficult writing, dysphagia, dysarthria, and
right-sided hemiparesis. NF1 had already been diagnosed on
a clinical basis and through the identification of the de novo
c.6792C>A variant in the neurofibromin gene, determining
the substitution of a tyrosine with a stop codon (p.Tyr2264∗)
resulting in a protein lacking 34 amino-acids (13).
MRI at admission showed (in addition to unidentified
bright objects located in the deep cerebellar white matter
and basal ganglia) a mass lesion with an irregular central
necrotic area in the left ponto-mesencephalic region (Figure 1).
Diffusion-weighted imaging (DWI) showed reduced diffusivity
along the ventrolateral margin of the lesion (minimum
absolute ADC value: 0.69 × 10−3 mm2/s). Magnetic resonance
spectroscopy (MRS), performed using a single-voxel point
resolved spectroscopy technique with an echo time of 144ms,
a repetition time of 2000ms, and 128 signal averages, showed
a Cho/NAA peak-height ratio of 3.44 and Cho/Cr ratio of
2.91 (Figure 1). An additional adjacent expansile lesion without
contrast enhancement or necrotic areas was found in themedulla.
The patient underwent biopsy of the ponto-mesencephalic
lesion and neuropathology demonstrated a diffuse midline
glioma H3K27M-mutant (glioblastoma). She was started with
focal radiotherapy in association with medical treatment with
vinorelbine and nimotuzumab.
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FIGURE 1 | Neuroimaging findings in NF1 patient 1. At admission, brain axial
T2-weighted and contrast-enhanced (CE) T1-weighted images show focal
areas of signal abnormalities without contrast enhancement in the globus
pallidus bilaterally, in keeping with typical unidentified bright objects (thin
arrows). Additional brain axial and sagittal T2-weighted and CE T1-weighted
images show mass lesions with a central necrotic area and irregular rim
enhancement in the left ponto-mesencephalic region, along with (arrowheads)
an adjacent expansile lesion involving the medulla without contrast
enhancement. Diffusion-weighted imaging (DWI) shows reduced diffusivity
along the ventrolateral margin of the ponto-mesencephalic lesion (thick arrow).
Post-contrast fluid attenuated inversion recovery (FLAIR-CE) image does not
reveal cerebral leptomeningeal dissemination. Sagittal CE T1-weighted image
of the spine does not show secondary lesions. Single-voxel magnetic
resonance spectroscopy (MRS) with an echo time of 144ms of the
ponto-mesencephalic lesion shows prominent increase of Cho/NAA and
Cho/Cr ratios. Three months later, following radiotherapy and first-line
chemotherapy treatment with vinorelbine and nimotuzumab, sagittal brain CE
T1-weighted image shows increased extension of the necrotic component
within the ponto-mesencephalic lesion. Axial CE T1-weighted and
post-contrast FLAIR images (FLAIR-CE) demonstrate leptomeningeal contrast
enhancement, in keeping with secondary disseminati5on, along the sylvian
fissures (thin arrow and thick arrows). Leptomeningeal dissemination is more
evident on sagittal CE T1-weighted image of the spine. Seven months after
diagnosis, following second-line treatment with etoposide and temozolomide,
axial CE T1-weighted and FLAIR-CE images show marked increase of nodular
leptomeningeal dissemination with extensive brain edema and subependymal
dissemination. Sagittal CE T1-weighted image of the spine show massive
secondary involvement around and within the spinal cord.
Follow-up MRI performed 3 months later, following
first-line treatment, revealed brain and spine leptomeningeal
dissemination, not present at diagnosis, in keeping with
progressive disease (Figure 1). The primary lesion demonstrated
an increased necrotic component with perilesional edema,
suggestive of radiation induced changes. Clinically, the patient
presented global deterioration of the neurological status, and she
underwent a cerebrospinal fluid diversion due to symptomatic
hydrocephalus. Subsequently, she was started with a second-line
chemotherapy course with etoposide and temozolomide.
She was re-evaluated after the first two cycles (5 months
since diagnosis) with brain and spinal imaging, demonstrating
further increase of the secondary dissemination; the primary
ponto-mesencephalic lesion presented decreased volume of the
necrotic component, supporting the diagnosis of radiation-
induced changes, and no evidence of local progression.
Clinical conditions worsened and a subsequent brain MRI
performed 7 months since diagnosis demonstrated a massive
brain and spine leptomeningeal dissemination with diffuse brain
edema (Figure 1). The patient died a few days later.
Case 2
A 13-year-old female presented with a recent history of
headache, episodes of vomiting, and left-sided hemiparesis.
Clinical examination revealed the presence of multiple café-
au-lait macules and axillary and inguinal freckling. She was
found to carry the c.5705C>A variant, which determines an
amino-acid substitution threonine with a lysine (p.Thr1902Lys).
This variant was transmitted by her affected mother. Brain and
spine MRI at admission showed (in addition to unidentified
bright objects in the deep cerebellar white matter, dorsal
pons, and in the globus pallidus bilaterally) an expansile and
infiltrating lesion with epicenter in the right thalamus extending
to the contralateral thalamus characterized by irregular contrast
enhancement (Figure 2).
On DWI, the minimum absolute ADC value of the lesion
was 0.68 × 10−3 mm2/s; MRS demonstrated a Cho/NAA peak-
height ratio of 11.26 and Cho/Cr ratio of 2.29. Perfusion-
weighted imaging, performed with pulsed arterial spin labeling
(ASL) technique, demonstrated a relative tumoral maximum
cerebral blood flow (rCBF max) of 1.5 (obtained by normalizing
the tumoral CBF max by a blood flow measurement from the
normal appearing contralateral gray matter in the temporal
lobe) (Figure 2). There was no evidence of leptomeningeal
dissemination. The patient also underwent cerebral 18F-DOPA
PET imaging demonstrating markedly increased uptake of the
lesion, with a maximum tumor/striatum ratio of 1.35 (Figure 2).
She underwent a stereotaxic biopsy and neuropathology
demonstrated an anaplastic astrocytoma, H3K27M-wild type.
She underwent treatment with radiotherapy and chemotherapy
with temozolomide and vinblastine.
Follow-up MRI performed 3 months later following first-line
treatment documented a significant disease progression without
leptomeningeal dissemination (Figure 2). Her neurological
status deteriorated rapidly and the patient died 5 months
after diagnosis.
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FIGURE 2 | Neuroimaging findings in NF1 patient 2. At admission, brain axial FLAIR and CE T1-weighted images show an infiltrating and expansile lesion with
epicenter in the right thalamus, partially involving the contralateral thalamus, with irregular contrast enhancement. DWI and corresponding apparent diffusion
coefficient (ADC) map show restricted diffusivity of the right thalamic portion of the lesion. Arterial spin labeling (ASL) perfusion-weighted imaging clearly demonstrates
increased perfusion of the lesion (thick arrow). Axial T2-weighted image shows small focal hyperintense areas located in the dorsal pons and deep cerebellar white
matter (thin arrows) in keeping with typical unidentified bright objects. Single-voxel MRS with an echo time of 144ms of the right thalamic region shows marked
increase of Cho/NAA and of Cho/Cr ratios. 18F-DOPA PET clearly demonstrates markedly increased uptake of the lesion. Three months later, following radiotherapy
and first-line chemotherapy treatment with temozolomide and vinorelbine, axial FLAIR and coronal T2-weighted images show increased extension of the infiltrating
components in the deep cerebral regions with prominent involvement of the brainstem (midbrain and dorsal pons). Axial and sagittal CE T1-weighted images show
concomitant marked increase of contrast enhancement. There was no evidence of leptomeningeal dissemination.
DISCUSSION
Pediatric HGGs are a relatively rare group of CNS neoplasms
with an aggressive behavior and poor prognosis (14, 15). About
50% of pediatric cerebral HGGs arise in midline structures
such as the brainstem and in particular the pons, the thalamus,
and rarely the cerebellum (14). In the revised 2016 WHO
classification of tumors of the CNS, and in the recent guidelines
of the cIMPACT-NOW (the Consortium to Inform Molecular
and Practical Approaches to CNS Tumor Taxonomy) Working
Committee 3, the DMG H3 K27M-mutant has been recognized
as a new diagnostic entity that should only include infiltrating
gliomas arising in midline structures (11, 16).
H3 K27M mutation results in substitution of the amino-acid
lysine to methionine at residue 27, inducing unique gain-of-
function mechanisms that lead to global reduction of H3 with
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trimethylated lysine 27 (H3K27me3). Even though the precise
role of H3 K27M mutation in tumorigenesis remains not clearly
defined, functional analysis has underscored its contribution to
inhibition of autophagy and abnormal cell-cycle control (17–20).
A recent study revealed also that H3 K27M mutation accelerates
brainstem tumorigenesis of HGGs from neonatal progenitor
cells (21). Genomic analysis of DMGs H3 K27M-mutant has
demonstrated a number of cooperating genetic alterations. In
particular, these tumors frequently present TP53 and ATRX
mutations (14, 20). In addition, the most recurrently mutated
gene in DIPGs H3 K27M-mutant after the histone variants
is the ACVR1, which encodes the activin A receptor type-1
transmembrane protein (20, 22).
In the setting of NF1, pediatric HGGs have been described
(4, 9, 14, 23–25) with a prevalence ranging from 0.28 to 5% (23).
NF1-related pediatric HGGs share genetic alterations of TP53
and CDKN2A with non-NF1 patients (26). A recent study (24)
also demonstrated that NF1HGGs “harbor frequentmutations of
ATRX associated with Alternative Lengthening of Telomere, and
are enriched in genetic alterations of transcription/chromatin
regulation and PI3 kinase pathways.” Frequent mutations of
ATRX drive aggressiveness in NF1 gliomas. Furthermore, “loss
of ATRX in NF1 HGGs is unique when considered within the
genetic contexts associated with ATRX mutations in sporadic
gliomas,” in which they are typically associated with pediatric H3
K27M-mutant DMGs (24).
Of note, due to their rarity, a child with a clinical diagnosis
of NF1 and HGG should be investigated for constitutional
mismatch-repair deficiency (CMMRD) if an NF1 mutation
has not been previously identified (27). CMMRD frequently
displays features reminiscent of NF1 (28). Genetic confirmation
of NF1 is therefore mandatory for genetic counseling to
families and because alternative therapies are available for
CMMRD-associated HGGs (27, 28). In particular, these patients
may benefit from immunotherapy with antibodies against
the programmed cell death protein-1, whereas temozolomide
should be avoided (27, 29). In our patients, genetic analysis
of NF1 was performed, identifying in patient 1 a c.6792C>A
variant in the NF1 gene determining a p.Tyr2264∗ premature
termination with skipping of exon 37 resulting in a protein
lacking 34 amino acids (13), while patient 2 was carrying the
c.5705C>A variant that determines an amino-acid substitution
p.Thr1902Lys. This variant is not present in gnomAD (Genome
Aggregation Database, https://gnomad.broadinstitute.org/); it
involves a highly conserved amino acid and was transmitted
by her affected mother. Eight different prediction tools, which
predict the possible impact of an amino-acid substitution on the
structure and function of a human protein using straightforward
physical and comparative considerations, indicate that the
variant has deleterious (D) effect (Appendix).
It is well-known that neurofibromin has an important
function in cancer development and progression. Bi-allelic loss of
neurofibromin confers a growth advantage in astrocytes in vitro
and is required for tumor formation (30, 31).
HGGs involving midline structures in the setting of NF1
are extremely rare, with few pediatric patients reported so far
(4, 9, 23, 25). In these prior reports, the association of midline
HGGs with NF1 was mainly based on a clinical NF1 diagnosis,
thus potentially not excluding a CMMRD.
Of note, one of our NF1 patients presented a DMGH3 K27M-
mutant and currently represents the first description in the
literature where this type of tumor is reported in association with
a genetically confirmed diagnosis of NF1. The rarity of DMGs H3
K27M-mutant in NF1 patients is underlined by a recent study
where genomic profile of 59 gliomas (22 children, 33 adults) was
evaluated. Remarkably, H3.3 histone variants were absent in all
59 cases (25).
Regarding our NF1 patients, none of them presented an optic
pathway glioma or a mass lesion in another district, or received
prior radiotherapy; typical unidentified bright objects were
present. In both cases, neoplasms demonstrated an unexpected
aggressive behavior, with no response to conventional therapies
and rapid leptomeningeal dissemination in one subject, with a
PFS of 3 months and an OS of 7 and 5 months.
Future studies are required in order to explore alternative
therapeutic approaches, including immunotherapy (32), in NF1
patients with DMGs.
Neuroimaging studies can play a pivotal role in suggesting
HGG, thus recommending biopsy sample in NF1 subjects.
Both patients presented areas of restricted diffusivity within
the lesions. MRS demonstrated pathologic increase of
Cho/NAA and Cho/Cr ratios. One NF1 subject underwent
both MRI perfusion imaging with ASL and molecular
imaging with 18F-DOPA PET, demonstrating increased
perfusion and markedly increased amino-acid uptake.
All these techniques have been demonstrated to add
significant information in discriminating low-grade from
high-grade cerebral gliomas, both midline and off-midline,
providing non-invasive microstructural, microvascular, and
metabolic information (12, 33, 34). In detail, DWI enables
estimation of brain tumor cellularity, and in our NF1 subjects,
reduced diffusivity of the lesions was suggestive of increased
cell density.
ASL allows quantification of cerebral blood flow correlated
with microvascular density, providing additional non-invasive
information of pediatric brain gliomas aggressiveness, as
demonstrated in case 2. MRS allows the estimation of normal
and abnormal brain metabolites, indicating loss of neuronal
integrity and increased turnover of myelin (33). Both subjects
presented an MRS pattern in keeping with increased biological
activity of the lesions. Among amino-acid PET tracers, 18F-
DOPA has demonstrated a high degree of correlation with tumor
grade in pediatric infiltrative astrocytomas (12, 34). Increased
18F-DOPA uptake is related to an overexpression of the L-type
amino-acid transporter 1, within highly proliferative tumoral
components (34, 35). Advanced MR imaging studies and/or
molecular amino-acid PET imaging are therefore recommended
in those NF1 subjects with suspected aggressive lesions on
conventional MRI in order to provide additional information
and increase diagnostic confidence. Of note, prior studies have
reported that thalamic localization, symptoms at diagnosis,
and diffusion restriction on MRI are elements suggestive of a
high-grade tumor in NF1 subjects (23, 25), as confirmed in
our study.
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In the non-NF1 population, we did not find statistically
significant differences in terms of PFS and OS between DMGs
H3 K27-mutant and non-histone mutant midline HGGs. In
the revised 2016 WHO classification of tumors of the CNS,
“for DMGs in general, the finding of an H3 K27M mutation,
confers a worse prognosis than that of wildtype cases” (11).
However, as reported by recent researches, non-unequivocal
findings are emerging regarding the prognostic role of H3
K27M mutation in DMGs, in accordance with our results. For
instance, recent studies highlighted that H3 K27M-wild-type
DIPGs (∼15% of the biopsied population) shared the same
unfavorable prognosis as H3 K27M-mutant DIPGs (36, 37),
independently of their underlying histological tumor grading.
Survival comparison between H3 K27M-mutant and wild-type
midline gliomas in adults also demonstrated that survival may
be similar or possibly improved if the mutation is present
(38, 39). Further and larger prospective studies are therefore
recommended to better define the prognostic significance of
H3 K27M mutation in DMGs, as also suggested in a recent
meta-analysis (40).
In both NF1 and non-NF1 HGGs, leptomeningeal
dissemination during treatment response evaluation was
revealed in five subjects, both H3K27M-mutant and wild
type, with no such evidence at admission. This finding
was clearly evaluable and more prominent in the spinal
compartment, when compared to the brain. Of note,
in the NF1 patient, the appearance of leptomeningeal
dissemination did not show a concomitant primary
lesion progression. Overall, these findings advise whole
brain and spine MRI studies in DMGs, at admission
and during follow-up, for a complete evaluation of the
disease status.
In the setting of NF1, leptomeningeal dissemination of
pediatric gliomas is an extremely rare event. We found only one
description of a pediatric patient with an HGG and diagnostic
criteria of NF1, where evidence of tumor dissemination was
reported (23). An additional single patient with NF1 and
a midline low-grade glioma (a pilocytic astrocytoma) with
secondary dissemination to the brain has been previously
described (41).
Among the limitations of our study, we are aware of its
retrospective nature and of the relatively small sample of
patients; however, we included only pediatric patients with
HGGs arising in midline brain structures, molecularly classified,
and NF1 subjects with genetic diagnosis, which are extremely
rare, particularly for a single center. The limited number
of NF1 patients did not allow performing formal statistical
analysis, and further multicenter studies with larger samples
of patients are needed to extend knowledge in this field.
Additional expression studies on H3 K27M-mutant DMGs
in NF1 patients are also needed to evaluate up- or down-
regulated genes and pathways that might represent a potential
therapeutic target.
In conclusion, according to our experience, HGGs
arising in midline brain structures in NF1 pediatric
patients present an aggressive behavior and an extremely
poor prognosis, worse than HGGs in non-NF1 patients,
independent of the presence or absence of H3 K27M
mutation. Lesions in evocative regions and with
features of increased biological activity on advanced
MRI or molecular amino-acid PET imaging may alert
clinicians, suggesting prompt neuropathological and
molecular investigations.
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APPENDIX
SIFT, Sorting Intolerant from Tolerant (https://sift.bii.a-
star.edu.sg/): D; PolyPhen-2, Polymorphism Phenotyping
v2 (http://genetics.bwh.harvard.edu/pph2/): HumDiv =
1.000 - HumVar = 0.999 (probably damaging); CADD,
Combined Annotation Dependent Depletion (https://cadd.
gs.washington.edu/snv): 34; DANN, omicX, deep neural
network (https://omictools.com/dann-tool): 0.992; FATHMM,
Functional Analysis through Hidden Markov Models (v2.3)
(http://fathmm.biocompute.org.uk/): −4.23; GERP++, omicX
(https://omictools.com/gerp-tool): 5.3; Mutation Taster (http://
www.mutationtaster.org/): D, D; PROVEAN, Protein Variation
Effect Analyzer (http://provean.jcvi.org/:D).
Furthermore this variant is not present in ClinVar;
the C>G change (c.5705C>G; p.Thr1902Arg - https://
www.ncbi.nlm.nih.gov/clinvar/variation/404539) and
the C>T change (c.5705C>T; p.Thr1902Met - https://
www.ncbi.nlm.nih.gov/clinvar/variation/187560) in
the same position (rs786203824; chr17: 29657472;
GRCh37.p13) have been defined in ClinVar of
uncertain significance.
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